SciELO - Scientific Electronic Library Online

 
vol.143 número2Evaluación de la calidad de vida de pacientes bipolares chilenos: propiedades psicométricas y utilidad diagnóstica de la versión chilena del cuestionario Quality of Life Bipolar Disorder (QoL.BD-CL)Propuesta de reformas a los prestadores públicos de servicios médicos en Chile: “fortaleciendo la opción pública” índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

BERLIN, Alejandro  y  FERNANDEZ, Mario I. Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies. Rev. méd. Chile [online]. 2015, vol.143, n.2, pp.223-236. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872015000200010.

Prostate cancer represents the second cancer-related cause of death in North American and Chilean men. The main treatment for incurable stages of disease is surgical or pharmacological castration. However, with time and despite the addition of anti-androgens, the disease progresses to a clinical state that has been commonly referred to as “hormone refractory”. In recent years, the concept of hormone refractoriness has been challenged and replaced by “castration resistance”, acknowledging that further and optimal hormonal manipulation can be attained, beyond achieving testosterone levels at castration range. The purpose of this review is to summarize the recent therapeutic breakthroughs in the management of metastatic castrate resistant prostate cancer (mCRPC), with greater emphasis in the newer hormonal therapy agents such as Abiraterone and Enzalutamide. Future combination and sequential treatment strategies are contextualized in the current era of personalized cancer medicine and genomic characterization of prostate cancer.

Palabras clave : Abiraterone; Enzalutamide; Prostatic neoplasms, castration-resistant.

        · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons